Annual report [Section 13 and 15(d), not S-K Item 405]

Revenues from Contracts and Significant Customers (Tables)

v3.26.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

($ in thousands)

  ​ ​ ​

2025

  ​ ​ ​

2024

Emrosi

​

$

14,745

​

$

—

Qbrexza

​

​

25,014

​

​

25,114

Accutane

​

​

12,882

​

​

19,407

Foam franchise products (Amzeeq & Zilxi)

​

​

5,859

​

​

6,652

Other / legacy product revenue

​

​

2,739

​

​

3,961

Collaboration revenue

​

​

—

​

​

1,500

Revenue – related party

​

 

—

​

 

41

Other revenue

​

​

2,023

​

 

1,000

Total net revenue

​

$

63,262

​

$

57,675